CTOs on the Move

Pure Bioscience

www.purebio.com

 
PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges. PURE`s proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate (SDC)- based antimicrobials, represent innovative advances in diverse markets and lead today`s global trend toward industry and consumer use of "green" products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to ...
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million
  • www.purebio.com
  • 771 Jamacha Road Suite 512
    El Cajon, CA USA 92019
  • Phone: 619.596.8600

Executives

Name Title Contact Details
Jason Kawata
 Vice President of Technology, Food Division Profile

Similar Companies

Lumen Bioscience Inc

We are a team of inspired individuals, driven by love of science, commitment to collaboration, and relentless pursuit of excellence. Lumen`s technology allows it to create clever new high-value products in spirulina (Arthrospira platens), a type of blue-green algae.

Hansa Biopharma

We are dedicated to developing lifesaving and life-altering treatments that can empower patients affected by rare immunologic conditions to live longer and healthier lives.

EGEN

EGEN is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Micell Technologies

Micell Technologies Inc is a Raleigh, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Entrada Therapeutics

Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company`s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system.